Insmed (INSM) Goldman Sachs 45th Annual Global Healthcare Conference summary

Growth outlook and commercial strategy

• Peak sales projections exceed $8 billion, driven by new indications and recent data, marking a major growth cycle from current $340–$360 million revenue guidance.

• Commercial infrastructure is already established and being expanded, with significant hiring underway to support anticipated launches.

• Physician enthusiasm and market preparation suggest rapid adoption for new therapies, with pricing studies indicating strong market access.

• Expansion into broader patient populations, including undiagnosed bronchiectasis in COPD and asthma, is expected to significantly increase addressable market.

• Financial position strengthened by recent $750 million financing and debt reduction, providing a robust runway for growth.

Brensocatib and ASPEN data insights

• ASPEN data showed statistically significant slowing of lung function decline and a clean safety profile, surprising and exciting the medical community.

• 20% reduction in pulmonary exacerbations and 40% improvement in probability of no exacerbations for a year were both highly meaningful.

• Quality of life improvements and comparable side effect profile to placebo further support strong clinical value.

• Ongoing analysis will determine optimal dosing, with 25 mg dose showing standout benefits.

• Expansion into CRS without nasal polyps and other indications is underway, leveraging the same mechanism of action.

Pipeline and future indications

• TPIP (treprostinil palmitil inhalation powder) is positioned as a best-in-class prostacyclin, with phase II data showing significant benefits and $2 billion+ peak sales potential.

• DPP-1 successor molecules are internally developed, with plans to target additional indications such as rheumatoid arthritis and lupus nephritis.

• Pillar Four aims to deliver 1–2 INDs per year, with new impactful medicines expected to emerge starting next year.

• ARIKAYCE is advancing into the frontline setting, with ENCORE data expected next year and potential for rapid uptake in larger patient populations.

• Strategic focus remains on profitability, balancing investment in innovation with internal development to avoid overreliance on acquisitions.